ストックスクリーナーアプリを入手
53.38
0.78%
-0.42
プレマーケット:
53.01
-0.37
-0.69%
前日終値:
$53.80
開ける：
$53.88
24時間の取引高:
2.19M
Relative Volume:
0.98
時価総額：
$4.96B
収益：
$536.20M
当期純損益:
$-45.64M
株価収益率:
-99.81
EPS:
-0.5348
ネットキャッシュフロー:
$-28.94M
1週間 パフォーマンス:
+9.90%
1か月 パフォーマンス:
+25.33%
6か月 パフォーマンス:
+48.90%
1年 パフォーマンス:
+263.62%
1日の値動き範囲:
$52.72
$54.38
1週間の範囲:
$46.54
$54.38
52週間の値動き範囲:
$13.88
$54.38
Travere Therapeutics Inc Stock (TVTX) Company Profile
名前
Travere Therapeutics Inc
セクター
電話
888-969-7879
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
53.38 | 5.00B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 繰り返されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-21 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-09 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-12-05 | アップグレード | Citigroup | Neutral → Buy |
| 2023-11-20 | 開始されました | Citigroup | Neutral |
| 2023-09-22 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 再開されました | Evercore ISI | Outperform |
| 2023-07-21 | 開始されました | JP Morgan | Overweight |
| 2023-06-07 | 再開されました | Piper Sandler | Neutral |
| 2023-05-22 | 開始されました | TD Cowen | Outperform |
| 2023-05-05 | アップグレード | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-21 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-12-14 | 開始されました | Stifel | Hold |
| 2022-12-05 | 開始されました | Wells Fargo | Overweight |
| 2022-09-21 | 開始されました | Bryan Garnier | Sell |
| 2022-07-14 | 再開されました | Canaccord Genuity | Buy |
| 2022-03-31 | 開始されました | Piper Sandler | Overweight |
| 2022-02-28 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-26 | ダウングレード | Wedbush | Outperform → Neutral |
すべてを表示
Travere Therapeutics Inc (TVTX) 最新ニュース
TVTX Maintained by Citigroup -- Price Target Raised to $70.00 - GuruFocus
Travere Therapeutics price target raised to $70 from $62 at Citi - TipRanks
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
TVTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? - Insider Monkey
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
TVTX Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $65 - GuruFocus
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo - The Globe and Mail
Roy Baynes to sell 4,500 TVTX shares via option exercise (TVTX) - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 reports 3,250-share sale - Stock Titan
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20 - Investor's Business Daily
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics stock hits 52-week high at 48.7 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 48.7 USD - Investing.com
3 Stocks That May Be Priced Below Their Estimated Value In June 2026 - simplywall.st
Travere Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Discipline and Rules-Based Execution in TVTX Response - Stock Traders Daily
Travere therapeutics CCO sells $101,417 in stock for tax obligations - Investing.com
Travere therapeutics chief research officer Rote sells $121,433 in shares - Investing.com
Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines - MSN
Travere buys BTK inhibitor for $1.1bn to treat kidney disease - BioXconomy
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion - ANTARA News
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines - BioPharma APAC
Travere Therapeutics (TVTX) Rises 2.72% as Stock Nears Key Resistance LevelAdaptive Moving Average - newsline.com
Travere Therapeutics, Inc. (TVTX) Stock: Phase 3 Extension Results Highlight Durable Proteinuria Reduction - parameter.io
Travere Therapeutics, Everest Medicines Partner to Advance Civorebrutinib - Contract Pharma
Travere Therapeutics CFO Cline sells $115,368 in company stock - Investing.com
Why is Travere Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Travere presents five-year FILSPARI data for rare kidney disease By Investing.com - Investing.com Australia
Travere Therapeutics (TVTX) Releases Promising Phase 3 Study Res - GuruFocus
Travere presents five-year FILSPARI data for rare kidney disease - Investing.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - The AI Journal
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63 - Business Wire
Everest Medicines signs $1 B deal with Travere Therapeutics for rare kidney diseases treatment - BioSpectrum Asia
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Guggenheim Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
TVTX Maintained by Citigroup -- Price Target Raised to $62 - GuruFocus
TVTX Reiterated by Wedbush -- Price Target Maintained at $55 - GuruFocus
TVTX: Portfolio expands with civorebrutinib and FILSPARI growth; key clinical catalysts ahead - TradingView
Everest Meds strikes licensing pact with Travere - The Pharma Letter
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases - Macau Business
EVEREST MED (01952.HK) Signs Exclusive License and Collaboration Agreement with Travere Therapeutics, Inc. (TVTX.US), to Receive USD112.5M Upfront Payment - AASTOCKS.com
TVTX Maintained by HC Wainwright & Co. -- Price Target Raised to $67 - GuruFocus
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Yahoo Finance
Travere licenses kidney disease drug from Everest Medicines By Investing.com - Investing.com India
Travere Therapeutics Inc (TVTX) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):